Purdue Pharma Opioid Lawsuit: The $7.4 Billion Sackler Settlement

The Litigation

Purdue Pharma, maker of OxyContin, and its owners, the Sackler family, faced a vast wave of lawsuits from states, local governments, tribes and individuals alleging they helped ignite the opioid epidemic through aggressive and misleading marketing of the painkiller. Purdue filed for bankruptcy in 2019, and the litigation became a defining test of how to hold both a company and its wealthy owners accountable for a public-health catastrophe.

The opioid crisis has been linked to hundreds of thousands of American deaths, which is the backdrop for the scale of these settlements.

The Supreme Court and the New Deal

An earlier bankruptcy plan would have given the Sacklers — who had not personally filed for bankruptcy — broad immunity from future opioid lawsuits in exchange for their payment. In June 2024, the US Supreme Court rejected that plan in a 5-4 decision, holding that bankruptcy law does not permit forcing such non-consensual releases on victims. A new agreement followed: a roughly $7.4 billion settlement in which the Sacklers pay about $6.5 billion over 15 years and Purdue nearly $900 million — and, crucially, the releases are consensual rather than automatic. A bankruptcy court confirmed the plan, backed by 55 attorneys general.

The distinction matters: the money is larger, aid to victims is accelerated, and the Sacklers no longer get automatic immunity.

Where the Money Goes

The bulk of the funds is directed to opioid abatement — addiction treatment, prevention and recovery programs run through states and localities — with a portion for individual victims and their families. Individual compensation runs through the settlement’s structured process, not a general sign-up site. The case is a landmark for both opioid accountability and the limits of bankruptcy shields.